RECURRENT HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial tests drug combo in fight against advanced head and neck cancer
Disease control OngoingThis large, late-stage trial is testing whether adding the drug bevacizumab to standard chemotherapy helps patients with advanced head and neck cancer that has returned or spread. The study enrolled 403 participants to see if the combination helps people live longer or slows canc…
Matched conditions: RECURRENT HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug duo tested to fight tough head and neck cancers
Disease control OngoingThis study is testing whether combining two existing drugs, pembrolizumab and cabozantinib, can help control advanced head and neck cancer that has come back or spread. It will involve about 36 patients whose cancer cannot be removed by surgery. The main goal is to see how many p…
Matched conditions: RECURRENT HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug cocktail aims to stall aggressive head and neck cancers
Disease control OngoingThis study tested whether adding the drug sorafenib to two standard chemotherapy drugs (carboplatin and paclitaxel) could better control advanced head and neck cancer that has returned or spread. It involved 48 patients with this difficult-to-treat cancer. The main goal was to se…
Matched conditions: RECURRENT HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug combo aims to tame tough head and neck cancers
Disease control OngoingThis study is testing whether combining an immunotherapy drug (cemiplimab) with two low-dose chemotherapy drugs works better for treating head and neck cancer that has returned or spread. It will involve about 46 patients whose cancer has come back or spread and who haven't had o…
Matched conditions: RECURRENT HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New Two-Drug attack on tough head and neck cancers
Disease control OngoingThis study is testing if adding a new drug called ipatasertib to a standard immunotherapy (pembrolizumab) works better for controlling advanced head and neck cancer that has returned or spread. It will involve about 52 adults who have not yet received treatment for their advanced…
Matched conditions: RECURRENT HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
New hope for tough head & neck cancers that resist First-Line treatment
Disease control OngoingThis study is for people with advanced head and neck cancer that has returned or spread after their first immunotherapy treatment stopped working. It compares three different drug combinations to see which one is better at controlling the cancer and helping patients live longer. …
Matched conditions: RECURRENT HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC